B
76/100
TG Therapeutics Claimed Company
TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. read more
HR or Marketing? Claim Your Free Employer Account
TG Therapeutics Outlook Employee Reviews
All
Positive
Constructive
What makes you most happy at work?
Overall, I like what I do
What's going wrong and how can it be improved?
There shouldn't be any nepotism
There is nepotism within the company.
What do you like best about your company?
There aren't any Outlook reviews of TG Therapeutics yet.
Be the first to contribute a review.
What would you most like to see improved at your company?
A non biases environment and better training in leadership
×